FDA OK's New Triplet Tx for Revlimid-Refractory Multiple Myeloma | MedPage Today
Progression-free survival with elotuzumab/pomalidomide/dexamethasone... | Download Scientific Diagram
Cancers | Free Full-Text | Recent Advances in the Treatment of Patients with Multiple Myeloma
Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers | Journal of Cancer Research and
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma | NEJM
Combination Therapies - POMALYST® (pomalidomide)
Empliciti (elotuzumab) for the Treatment of Multiple Myeloma, USA
EHA Library - The official digital education library of European Hematology Association (EHA)
Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone - ScienceDirect
Multiple Myeloma with a Special Focus on Precision Medicine | Published in healthbook TIMES Oncology Hematology
Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab. | Semantic Scholar
Progression-free (dashed line) and overall survival (solid line) with... | Download Scientific Diagram
EMN 29 - Seli-Pom-Dex Vs Elo-Pom-Dex - Multiple Myeloma Clinical Trials
Pomalidomide, Dexamethasone, & Elotuzumab Combo Trial
Population pharmacokinetic and exposure–response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma | Cancer Chemotherapy and Pharmacology
Characterization of Synergistic Selinexor Combinations of Dexamethasone, Pomalidomide, Elotuzumab and Daratumumab in Primary MM Samples Ex Vivo - ScienceDirect
Continuous Elotuzumab, Pomalidomide and Dexamethasone Maintenance Following Second Autologous Transplant for Multiple Myeloma: Results of a Prospective, Phase 2 Multicenter Trial - Transplantation and Cellular Therapy, Official Publication of the ...
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma | NEJM
Pharmaceuticals | Free Full-Text | Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study | Blood Cancer Journal
Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab - Hermann Einsele, Martin Schreder, 2016
Elotuzumab Plus Pomalidomide and Dexamethasone for Multiple Myeloma - YouTube
NEJM on X: "New research into elotuzumab plus pomalidomide and dexamethasone for #MultipleMyeloma explained in Quick Take video: https://t.co/Aa2Q1U86zg https://t.co/YJK9tdF7wE" / X
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial - The Lancet Haematology
FDA
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials | Haematologica
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial | Journal of Clinical Oncology
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology
